Effect on growth of two different dexamethasone courses for preterm infants at risk of chronic lung disease. A

C Romagnoli1, E Zecca, G Vento

  • 1Department of Paediatrics, Division of Neonatology, Catholic University of the Sacred Heart, Rome, Italy. cromagnoli@rm.unicatt.it

Pharmacology
|October 26, 1999
PubMed

Insights

Dexamethasone treatment in preterm infants with chronic lung disease risk temporarily slows weight gain but leads to catch-up growth. Higher doses may negatively impact head growth, suggesting potential adverse effects on brain development.

Area of Science:

  • Neonatal Medicine
  • Pediatric Pharmacology
  • Growth and Development

Background:

  • Preterm infants are at high risk for chronic lung disease (CLD).
  • Dexamethasone is used to manage CLD in preterm infants, but its effects on growth require evaluation.
  • Understanding the optimal dexamethasone regimen is crucial for balancing therapeutic benefits and adverse effects.

Purpose of the Study:

  • To evaluate the impact of two different dexamethasone treatment courses on the growth of preterm infants at risk for CLD.
  • To compare the effects of moderately early versus early dexamethasone administration on infant growth parameters.
  • To identify potential dose-related adverse effects of dexamethasone on infant development.

Main Methods:

  • A randomized study involving two phases, each with a dexamethasone-treated group and a control group.
  • Phase 1: 15 infants received 14 days of dexamethasone (4.75 mg/kg total dose) from day 10; 15 controls.
  • Phase 2: 15 infants received 7 days of dexamethasone (2.38 mg/kg total dose) from day 4; 15 controls.

Main Results:

  • Dexamethasone treatment significantly reduced weight gain during therapy but was followed by catch-up growth.
  • At 30 days of life, weight and length gains were similar between treated and control groups.
  • The moderately early, higher-dose dexamethasone group showed significantly poorer head growth at 30 days.

Conclusions:

  • Dexamethasone treatment causes a temporary reduction in weight gain, with subsequent catch-up growth.
  • Higher-dose, moderately early dexamethasone may have adverse effects on postnatal brain growth, indicated by poorer head growth.
  • Further research into dose-related adverse effects of dexamethasone on preterm infant neurodevelopment is warranted.

Related Concept Videos